Home
NBIX
NBIX News

Latest Neurocrine Biosciences Inc. (NBIX) News on February 23, 2025

Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now?

Insider Monkey

a day ago

Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now?

Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest

Simply Wall St.

a day ago

Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest

MT Newswires

2 days ago

Sector Update: Health Care Stocks Mixed Premarket Friday

MT Newswires

2 days ago

Neurocrine Biosciences Approves $500 Million Share Repurchase Program

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

PR Newswire

2 days ago

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

Argus Research

4 days ago

NBIX: Lowering target price to $120.00

Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January

Insider Monkey

4 days ago

Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January

MT Newswires

5 days ago

Neurocrine Biosciences Insider Sold Shares Worth $1,613,923, According to a Recent SEC Filing

MT Newswires

12 days ago

Deutsche Bank Initiates Coverage on Neurocrine Biosciences With Hold Rating, $138 Price Target

Why Neurocrine Biosciences Stock Sank Today

Motley Fool

12 days ago

Why Neurocrine Biosciences Stock Sank Today

MT Newswires

13 days ago

UBS Adjusts Neurocrine Biosciences Price Target to $154 From $176, Maintains Buy Rating

Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week

Insider Monkey

13 days ago

Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week

Here’s Why Neurocrine Biosciences Inc. (NBIX) Crashed on Friday

Insider Monkey

14 days ago

Here’s Why Neurocrine Biosciences Inc. (NBIX) Crashed on Friday

Neurocrine Biosciences' (NASDAQ:NBIX) underlying earnings growth outpaced the notable return generated for shareholders over the past three years

Simply Wall St.

15 days ago

Neurocrine Biosciences' (NASDAQ:NBIX) underlying earnings growth outpaced the notable return generated for shareholders over the past three years

Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug

Investor's Business Daily

15 days ago

Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug

These Stocks Moved the Most Today: Amazon, Tesla, Uber, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More

Barrons.com

15 days ago

These Stocks Moved the Most Today: Amazon, Tesla, Uber, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

Benzinga

15 days ago

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

MT Newswires

15 days ago

RBC Capital Adjusts Price Target on Neurocrine Biosciences to $148 From $154, Keeps Sector Perform Rating

MT Newswires

16 days ago

Wedbush Adjusts Price Target on Neurocrine Biosciences to $147 From $157, Keeps Outperform Rating

MT Newswires

16 days ago

Sector Update: Health Care Stocks Lower Pre-Bell Friday

These Stocks Are Moving the Most Today: Amazon, Tesla, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More

Barrons.com

16 days ago

These Stocks Are Moving the Most Today: Amazon, Tesla, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More

MT Newswires

16 days ago

Sector Update: Health Care

Thomson Reuters StreetEvents

16 days ago

Q4 2024 Neurocrine Biosciences Inc Earnings Call

GuruFocus.com

16 days ago

Neurocrine Biosciences Inc (NBIX) Q4 2024 Earnings Call Highlights: Record INGREZZA Growth and ...

Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates

Zacks

16 days ago

Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates

Argus Research

18 days ago

NBIX: Raising target price to $160.00

MT Newswires

18 days ago

Neurocrine Biosciences Insider Sold Shares Worth $413,967, According to a Recent SEC Filing

Neurocrine Biosciences, Inc. (NBIX): Among the Best Low Risk High Growth Stocks To Invest In Now

Insider Monkey

18 days ago

Neurocrine Biosciences, Inc. (NBIX): Among the Best Low Risk High Growth Stocks To Invest In Now

Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Zacks

19 days ago

Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results

PR Newswire

23 days ago

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results

MT Newswires

24 days ago

Neurocrine Biosciences Insider Sold Shares Worth $21,836,503, According to a Recent SEC Filing

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Zacks

24 days ago

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Argus Research

25 days ago

NBIX: Raising target price to $158.00

MT Newswires

25 days ago

Neurocrine Biosciences Begins Phase 3 Study of Osavampator in Major Depressive Disorder

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

Benzinga

25 days ago

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults

PR Newswire

a month ago

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults

MT Newswires

a month ago

Neurocrine Amends Collaboration with Takeda on Osavampator

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

PR Newswire

a month ago

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

PR Newswire

a month ago

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

MT Newswires

a month ago

Wedbush Lifts Price Target on Neurocrine Biosciences to $157 From $154, Keeps Outperform Rating

Argus Research

a month ago

NBIX: Rating increased to a HOLD

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

PR Newswire

a month ago

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

MT Newswires

a month ago

Neurocrine Biosciences Insider Sold Shares Worth $9,197,550, According to a Recent SEC Filing

Argus Research

a month ago

NBIX: Raising target price to $112.00

Exploring High Growth Tech Stocks in January 2025

Simply Wall St.

a month ago

Exploring High Growth Tech Stocks in January 2025

MT Newswires

a month ago

UBS Raises Price Target on Neurocrine Biosciences to $162 From $142, Keeps Buy Rating

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

PR Newswire

a month ago

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

MT Newswires

2 months ago

RBC Boosts Price Target on Neurocrine Biosciences to $159 From $136, Keeps Sector Perform Rating

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PR Newswire

2 months ago

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences Stock Sees RS Rating Upgrade

Investor's Business Daily

2 months ago

Neurocrine Biosciences Stock Sees RS Rating Upgrade

Argus Research

2 months ago

NBIX: What does Argus have to say about NBIX?

Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?

Zacks

2 months ago

Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?

MT Newswires

2 months ago

Wedbush Raises Price Target on Neurocrine Biosciences to $154 From $148, Keeps Outperform Rating

MT Newswires

2 months ago

Neurocrine Biosciences Starts Commercial Sales of New Congenital Adrenal Hyperplasia Treatment

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

PR Newswire

2 months ago

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

Argus Research

2 months ago

NBIX: Raising target price to $144.00

Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug

Investor's Business Daily

2 months ago

Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential

Benzinga

2 months ago

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential

MT Newswires

2 months ago

Neurocrine Biosciences' Crenessity Approved by FDA for Classic Congenital Adrenal Hyperplasia

Neurocrine Wins FDA Approval For Genetic Disorder Drug

Investor's Business Daily

2 months ago

Neurocrine Wins FDA Approval For Genetic Disorder Drug

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

PR Newswire

2 months ago

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.

2 months ago

Exploring Three High Growth Tech Stocks In The United States

Argus Research

2 months ago

NBIX: Raising target price to $135.00

Argus Research

3 months ago

NBIX: Lowering target price to $132.00

Why Is Neurocrine Biosciences, Inc. (NBIX) Among the Best High Growth Healthcare Stocks to Invest In Now?

Insider Monkey

3 months ago

Why Is Neurocrine Biosciences, Inc. (NBIX) Among the Best High Growth Healthcare Stocks to Invest In Now?

Why Neurocrine Biosciences (NBIX) Is the Most Profitable Pharmaceutical Stock Right Now?

Insider Monkey

3 months ago

Why Neurocrine Biosciences (NBIX) Is the Most Profitable Pharmaceutical Stock Right Now?

Neurocrine Biosciences to Participate at Investor Conferences in December

PR Newswire

3 months ago

Neurocrine Biosciences to Participate at Investor Conferences in December

Argus Research

3 months ago

NBIX: Raising target price to $133.00

High Growth Tech Stocks Featuring Three Prominent US Companies

Simply Wall St.

3 months ago

High Growth Tech Stocks Featuring Three Prominent US Companies

Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality

Simply Wall St.

3 months ago

Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

PR Newswire

4 months ago

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

Argus Research

4 months ago

NBIX: Raising target price to $128.00

Neurocrine Biosciences to Participate at Investor Conferences in November

PR Newswire

4 months ago

Neurocrine Biosciences to Participate at Investor Conferences in November

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

PR Newswire

4 months ago

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia

PR Newswire

4 months ago

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia

GuruFocus.com

4 months ago

Neurocrine Biosciences Inc (NBIX) Q3 2024 Earnings Call Highlights: Strong Sales and Strategic ...

Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight

GuruFocus.com

4 months ago

Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight

Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

4 months ago

Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates

Zacks

4 months ago

Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates

MT Newswires

4 months ago

Neurocrine Biosciences' Q3 Non-GAAP Earnings, Revenue Advance

Associated Press Finance

4 months ago

Neurocrine: Q3 Earnings Snapshot

Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

PR Newswire

4 months ago

Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

Zacks

4 months ago

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

Zacks

4 months ago

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

State Street Corp's Strategic Acquisition in Neurocrine Biosciences Inc

GuruFocus.com

4 months ago

State Street Corp's Strategic Acquisition in Neurocrine Biosciences Inc

Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds?

Insider Monkey

4 months ago

Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds?

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

4 months ago

Exploring Three High Growth Tech Stocks in the United States

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

PR Newswire

4 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

Argus Research

4 months ago

NBIX: Lowering target price to $117.00

MT Newswires

5 months ago

RBC Trims Price Target on Neurocrine Biosciences to $133 From $136, Keeps Sector Perform Rating

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Simply Wall St.

5 months ago

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use

PR Newswire

5 months ago

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use

Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit

PR Newswire

5 months ago

Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit

MT Newswires

5 months ago

Voyager Therapeutics Says Third Gene Therapy Development Candidate Selected Under Neurocrine Collaboration

Neurocrine Biosciences, Inc. (NBIX): Hedge Funds Are Bullish on This Aggressive Growth Stock

Insider Monkey

5 months ago

Neurocrine Biosciences, Inc. (NBIX): Hedge Funds Are Bullish on This Aggressive Growth Stock

Neurocrine’s Phase II schizophrenia trial fails to meet primary endpoint

Clinical Trials Arena

5 months ago

Neurocrine’s Phase II schizophrenia trial fails to meet primary endpoint

MT Newswires

5 months ago

Neurocrine Plans to Halt Luvadaxistat Development After Study Fails to Meet Target

Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

PR Newswire

5 months ago

Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

PR Newswire

5 months ago

Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Nxera wins $35m after Phase II schizophrenia trial success

Pharmaceutical Technology

6 months ago

Nxera wins $35m after Phase II schizophrenia trial success

Share on Social Networks: